16:54 , May 25, 2017 |  BC Innovations  |  Translation in Brief

Neutralizing neutrophils

Scientists at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) uncovered a new role for a known kinase in neutrophil activation and blocked the protein to treat inflammatory diseases. Pathway data suggest targeting the kinase...
19:39 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In a mouse model of PDAC, CXCR2 knockout decreased tumor growth and the number of tumor-infiltrating neutrophils and increased survival...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, high levels of CXCR2 in neutrophils at the tumor borders correlated with disease...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); chemokine CXC motif ligand 5 (CXCL5; ENA78)

Cancer INDICATION: Prostate cancer Mouse and cell culture studies suggest CXCR2 inhibitors could help treat invasive prostate cancer. In a mouse model of highly invasive prostate cancer, tumor levels of CXCL5 and CXCR2-expressing myeloid-derived suppressor...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis Chemokine CXC motif ligand 5 (CXCL5; ENA78); CXC chemokine receptor 2 (CXCR2; IL8RB) Mouse studies suggest inhibiting the CXCL5-CXCR2...
07:00 , Apr 8, 2013 |  BioCentury  |  Strategy

AstraZeneca's reset

After spending at least $7 billion for late-stage assets in 2012, AstraZeneca plc believes it now has sufficient value in its Phase II/III pipeline to restore long-term growth. The attention of business development is now...
07:00 , Aug 9, 2012 |  BC Innovations  |  Targets & Mechanisms

CXCR2 antagonists in breast cancer

A team at the Memorial Sloan-Kettering Cancer Center has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mouse models of metastatic breast cancer. 1 The team is working on additional preclinical...
07:00 , Sep 22, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension CXC chemokine receptor 2 (CXCR2; IL8RB) In vitro and mouse studies suggest CXCR2 antagonists could help treat familial pulmonary...